




Brazilian Modeling of COVID-19 (BRAM-COD): a Bayesian Monte Carlo approach for COVID-19 spread in a limited data set context

Samy Dana,  Alexandre B Simas, Bruno A Filardi, Rodrigo N Rodriguez,  Leandro Lane da Costa Valiengo,  Jose Gallucci-Neto

doi: <http://dx.doi.org/10.1101/2020.04.29.20081174>

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

[Abstract](#)[Info/History](#)[Metrics](#)[Preview PDF](#)

Abstract

Background: The new coronavirus respiratory syndrome disease (COVID-19) pandemic has become a major health problem worldwide. Many attempts have been devoted to modeling the dynamics of new infection rates, death rates, and the impact of the disease on health systems and the world economy. Most of these modeling concepts use the Susceptible-Infectious-Susceptible (SIS) and Susceptible-Exposed-Infected-Recovered (SEIR) compartmental models; however, wide imprecise outcomes in forecasting can occur with these models in the context of poor data, low testing levels, and a nonhomogeneous population. **Objectives:** To predict Brazilian ICU beds demand over time and during COVID-19 pandemic peak. **Methods:** In the present study, we describe a Bayesian COVID-19 model combined with a Hamiltonian Monte Carlo algorithm to forecast quantitative predictions of infections, number of deaths and the demand for critical care beds in the next month in the Brazilian context of scarce data availability. We also estimated COVID-19 spread tendency in the state of Sao Paulo and forecasted the demand for critical care beds, as Sao Paulo is the epicenter of the Latin America pandemic. **Results:** Our model estimated that the number of infected individuals would be approximately 6.5 million (median) on April 25, 2020, and would reach 16 to 17 million (median) by the end of August 2020 in Brazil. The probability that an infected individual requires ICU-level care in Brazil is 0.5833%. Our model suggests that the current level of mitigation seen in Sao Paulo is sufficient to reach $R_t < 1$, thus attaining a peak in the short term. In Sao Paulo state, the total number of deaths is estimated to be around 9,000 (median) with the 2.5% quantile being 6,600 deaths and the 97.5% quantile being around 13,350 deaths. Also, Sao Paulo will not attain its maximum capacity of ICU beds if the current trend persists over the long term. **Conclusions:** The COVID-19

pandemic should peak in Brazil between May 8 and May 20, 2020 with a fatality rate lower than that suggested in the literature. The northern and northeastern regions of Brazil will suffer from a lack of available ICU beds, whereas the southeastern, southern, and central-western regions appear to have sufficient ICU beds only if they share private system beds with the publicly funded Unified Health System (SUS). The model predicts that, if the current policies and population behavior are maintained throughout the forecasted period, by the end of August 2020, Brazil will have around 12% of its population immune to COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Copyright

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Tweets referencing this article:

Cenira

@CeniradeP

Fui obrigada a ler esta meia pagina considerada "versão científica" que vai ao contrario de tantas outras milhares de paginas já publicadas por sérios cientistas em todo o mundo que estão trabalhando incansavelmente para entender o COVID19. Vc tem sangue

12:29AM

Walaq Lima

@walaq_lima

RT @tiagotvv: Thread: Este preprint do @samydana et al. é bem interessante e vale a leitura. Não estou por dentro dos meandros matemáticos...

12:19AM

0 Comments [medrxiv](#) [Disqus' Privacy Policy](#)

[Login](#)

[Recommend](#) 1

[Tweet](#)

[Share](#)

[Sort by Newest](#)



Start the discussion...

LOG IN WITH

OR SIGN UP WITH DISQUS [?](#)

Name

Be the first to comment.

[Subscribe](#) [Add Disqus to your site](#) [Add DisqusAdd](#) [Do Not Sell My Data](#)

[^ Back to top](#)

[← Previous](#)

[Next →](#)

Posted May 03, 2020.

[Download PDF](#)

[Data/Code](#)

[Email](#)

[Share](#)

[Citation Tools](#)

Tweet

Curtir 6

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

Health Policy 

Subject Areas

All Articles

Addiction Medicine
Allergy and Immunology
Anesthesia
Cardiovascular Medicine
Dentistry and Oral Medicine
Dermatology
Emergency Medicine
Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Epidemiology
Forensic Medicine
Gastroenterology
Genetic and Genomic Medicine
Geriatric Medicine
Health Economics
Health Informatics
Health Policy
Health Systems and Quality Improvement
Hematology
HIV/AIDS
Infectious Diseases (except HIV/AIDS)
Intensive Care and Critical Care Medicine
Medical Education
Medical Ethics
Nephrology
Neurology
Nursing
Nutrition
Obstetrics and Gynecology
Occupational and Environmental Health
Oncology
Ophthalmology

Orthopedics
Otolaryngology
Pain Medicine
Palliative Medicine
Pathology
Pediatrics
Pharmacology and Therapeutics
Primary Care Research
Psychiatry and Clinical Psychology
Public and Global Health
Radiology and Imaging
Rehabilitation Medicine and Physical Therapy
Respiratory Medicine
Rheumatology
Sexual and Reproductive Health
Sports Medicine
Surgery
Toxicology
Transplantation
Urology